Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): An oncoprotein with many hands

Oncotarget

Volumn 5, Issue 13, 2014, Pages 4581-4602

  De, Pradip ^a,b   Carlson, Jennifer ^a   Leyland Jones, Brian ^a,b   Dey, Nandini ^a,b  

^a Avera Research Institute   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Biomarkers; c MYC; Cancers; CIP2A; PP2A; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; MYC PROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG; AUTOANTIGEN; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN BINDING; TUMOR MARKER;

ARTICLE; BILE DUCT CARCINOMA; BLADDER CANCER; BONE MARROW CANCER; BRAIN CANCER; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; CELL TRANSFORMATION; COLORECTAL CANCER; COLORECTAL CARCINOMA; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MOUTH CARCINOMA; NONHUMAN; OSTEOSARCOMA; OVARY CARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PREDICTIVE VALUE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; SOLID TUMOR; STOMACH CANCER; TONGUE CANCER; UTERINE CERVIX CARCINOMA; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOLOGICAL MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOANTIGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; MODELS, GENETIC; NEOPLASMS; PROTEIN BINDING; PROTEIN PHOSPHATASE 2; TUMOR MARKERS, BIOLOGICAL;

EID: 84904963010     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2127     Document Type: Article

References (159)

1. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57-70.
2. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, Ala-Aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grenman R, Kast J, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007; 130(1):51-62.
3. Westermarck J and Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends in molecular medicine. 2008; 14(4):152-160.
4. Perrotti D and Neviani P. Protein phosphatase 2A: a target for anticancer therapy. The lancet oncology. 2013; 14(6):e229-238.
5. Kalev P and Sablina AA. Protein phosphatase 2A as a potential target for anticancer therapy. Anti-cancer agents in medicinal chemistry. 2011; 11(1):38-46.
6. Polakis P. Wnt signaling and cancer. Genes & development. 2000; 14(15):1837-1851.
7. Creyghton MP, Roel G, Eichhorn PJ, Hijmans EM, Maurer I, Destree O and Bernards R. PR72, a novel regulator of Wnt signaling required for Naked cuticle function. Genes & development. 2005; 19(3):376-386.
8. Creyghton MP, Roel G, Eichhorn PJ, Vredeveld LC, Destree O and Bernards R. PR130 is a modulator of the Wnt-signaling cascade that counters repression of the antagonist Naked cuticle. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(14):5397-5402.
9. Eichhorn PJ, Creyghton MP and Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochimica et biophysica acta. 2009; 1795(1):1-15.
10. Eichhorn PJ, Creyghton MP, Wilhelmsen K, van Dam H and Bernards R. A RNA interference screen identifies the protein phosphatase 2A subunit PR55gamma as a stress-sensitive inhibitor of c-SRC. PLoS genetics. 2007; 3(12):e218.
11. Arnold HK and Sears RC. Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Molecular and cellular biology. 2006; 26(7):2832-2844.
12. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell. 2007; 130(1):21-24.
13. Sablina AA and Hahn WC. The role of PP2A A subunits in tumor suppression. Cell adhesion & migration. 2007; 1(3):140-141.
14. Khanna A, Pimanda JE and Westermarck J. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Cancer research. 2013; 73(22):6548-6553.
15. De P, Carlson J, Leyland-Jones B and Dey N. Functions of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A): Role in Breast Oncogenesis communicated. 2014.
16. Niemela M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernila P, Kallioniemi OP, Joensuu H, Hautaniemi S and Westermarck J. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene. 2012; 31(39):4266-4278.
17. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr. and Kinzler KW. Cancer genome landscapes. Science. 2013; 339(6127):1546-1558.
18. Kim JS, Kim EJ, Oh JS, Park IC and Hwang SG. CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1. Cancer research. 2013; 73(22):6667-6678.
19. Jeong AL, Lee S, Park JS, Han S, Jang CY, Lim JS, Lee MS and Yang Y. Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity. The Journal of biological chemistry. 2014; 289(1):28-40.
20. Kerosuo L, Fox H, Perala N, Ahlqvist K, Suomalainen A, Westermarck J, Sariola H and Wartiovaara K. CIP2A increases self-renewal and is linked to Myc in neural progenitor cells. Differentiation; research in biological diversity. 2010; 80(1):68-77.
21. Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemela M, Khanna A, Chan EK, Kahari VM, Kellokumpu-Lehtinen PL, Sansom OJ, Evan GI, Junttila MR, Ryan KM, Marine JC, Joensuu H, et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer discovery. 2013; 3(2):182-197.
22. Khanna A. BC, Schreck I., Weiss C., Visakorpi T., Ristimaki A., Westermarck J. (2011). Chk1-CIP2A pathway independent of ATM-ATR. AACR 102nd Annual Meeting. (Orlando FL: Cancer Research).
23. Khanna A, Kauko O, Bockelman C, Laine A, Schreck I, Partanen JI, Szwajda A, Bormann S, Bilgen T, Helenius M, Pokharel YR, Pimanda J, Russel MR, Haglund C, Cole KA, Klefstrom J, et al. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. Cancer research. 2013; 73(22):6757-6769.
24. Mathiasen DP, Egebjerg C, Andersen SH, Rafn B, Puustinen P, Khanna A, Daugaard M, Valo E, Tuomela S, Bottzauw T, Nielsen CF, Willumsen BM, Hautaniemi S, Lahesmaa R, Westermarck J, Jaattela M, et al. Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene. 2012; 31(3):390-401.
25. Zhao Y, Li Y, Han J, Liu T, Guan Q, Zhao P, Guo L, Liu K and He D. Helicobacter pylori enhances CIP2A expression and cell proliferation via JNK2/ATF2 signaling in human gastric cancer cells. International journal of molecular medicine. 2014; 33(3):703-710.
26. Puustinen P, Rytter A, Mortensen M, Kohonen P, Moreira JM and Jaattela M. CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. The Journal of cell biology. 2014; 204(5):713-727.
27. Junttila MR and Westermarck J. Mechanisms of MYC stabilization in human malignancies. Cell cycle. 2008; 7(5):592-596.
28. Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck AH and Sabatini DM. A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity. Cancer discovery. 2014; 4(5):554-563.
29. Zoncu R, Efeyan A and Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nature reviews Molecular cell biology. 2011; 12(1):21-35.
30. Efeyan A and Sabatini DM. Nutrients and growth factors in mTORC1 activation. Biochemical Society transactions. 2013; 41(4):902-905.
31. Efeyan A and Sabatini DM. mTOR and cancer: many loops in one pathway. Current opinion in cell biology. 2010; 22(2):169-176.
32. Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM and Yung WK. Antitumor activity of NVP-BKM120-a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18(1):184-195.
33. Park E, Park J, Han SW, Im SA, Kim TY, Oh DY and Bang YJ. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. International journal of oncology. 2012; 40(4):1259-1266.
34. Huang S and Houghton PJ. Mechanisms of resistance to rapamycins. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 2001; 4(6):378-391.
35. Li Y, Wang X, Yue P, Tao H, Ramalingam SS, Owonikoko TK, Deng X, Wang Y, Fu H, Khuri FR and Sun SY. Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation. The Journal of biological chemistry. 2013; 288(19):13215-13224.
36. Van Hoof C and Goris J. PP2A fulfills its promises as tumor suppressor: which subunits are important? Cancer cell. 2004; 5(2):105-106.
37. Soo Hoo L, Zhang JY and Chan EK. Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene. 2002; 21(32):5006-5015.
38. Jung HM, Phillips BL and Chan EK. miR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3zeta. Molecular cancer. 2014; 13:80.
39. Wiegering A, Pfann C, Uthe FW, Otto C, Rycak L, Mader U, Gasser M, Waaga-Gasser AM, Eilers M and Germer CT. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PloS one. 2013; 8(10):e75292.
40. Bockelman C, Koskensalo S, Hagstrom J, Lundin M, Ristimaki A and Haglund C. CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer biology & therapy. 2012; 13(5):289-295.
41. Cristobal I, Manso R, Rincon R, Carames C, Senin C, Borrero A, Martinez-Useros J, Rodriguez M, Zazo S, Martinez-Aguilera O, Madoz-Gurpide J, Rojo F and Garcia-Foncillas J. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Molecular cancer therapeutics. 2014.
42. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ and Wang EH. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Annals of surgical oncology. 2011; 18(3):857-865.
43. Sung WW and Lee H. The role of interleukin-10 in the progression of human papillomavirus-associated lung carcinoma. Oncoimmunology. 2013; 2(9):e25854.
44. Sung WW, Wang YC, Lin PL, Cheng YW, Chen CY, Wu TC and Lee H. IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(15):4092-4103.
45. Zhai M, Cong L, Han Y and Tu G. CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013.
46. Qu W, Li W, Wei L, Xing L, Wang X and Yu J. CIP2A is overexpressed in esophageal squamous cell carcinoma. Medical oncology. 2012; 29(1):113-118.
47. Rantanen T, Kauttu T, Akerla J, Honkanen T, Krogerus L, Salo J, Paavonen T and Oksala N. CIP2A expression and prognostic role in patients with esophageal adenocarcinoma. Medical oncology. 2013; 30(3):684.
48. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J and Ristimaki A. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. Journal of the National Cancer Institute. 2009; 101(11):793-805.
49. Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J and Xu D. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(12):3722-3728.
50. Zhao D, Liu Z, Ding J, Li W, Sun Y, Yu H, Zhou Y, Zeng J, Chen C and Jia J. Helicobacter pylori CagA upregulation of CIP2A is dependent on the Src and MEK/ERK pathways. Journal of medical microbiology. 2010; 59(Pt 3):259-265.
51. Wang L, Gu F, Ma N, Zhang L, Bian JM and Cao HY. CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34(4):2309-2313.
52. Farrell AS, Allen-Petersen B, Daniel CJ, Wang X, Wang Z, Rodriguez S, Impey S, Oddo J, Vitek MP, Lopez C, Christensen DJ, Sheppard B and Sears RC. Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer. Molecular cancer research: MCR. 2014.
53. Yi F, Ni W, Liu W, Bai J and Li W. Expression and biological role of CIP2A in human astrocytoma. Molecular medicine reports. 2013; 7(5):1376-1380.
54. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thezenas S and Westermarck J. CIP2A is associated with human breast cancer aggressivity. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(16):5092-5100.
55. Choi YA, Park JS, Park MY, Oh KS, Lee MS, Lim JS, Kim KI, Kim KY, Kwon J, Yoon do Y, Moon EY and Yang Y. Increase in CIP2A expression is associated with doxorubicin resistance. FEBS letters. 2011; 585(5):755-760.
56. Kang J, Sergio CM, Sutherland RL and Musgrove EA. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer. 2014; 14:32.
57. Yu G, Liu G, Dong J and Jin Y. Clinical implications of CIP2A protein expression in breast cancer. Medical oncology. 2013; 30(2):524.
58. Laine A and Westermarck J. Molecular Pathways: Harnessing E2F1 Regulation for Prosenescence Therapy in p53 Defective Cancer Cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014.
59. Baldacchino S, Saliba C, Petroni V, Fenech AG, Borg N and Grech G. Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720. The EPMA journal. 2014; 5(1):3.
60. Huang LP, Savoly D, Sidi AA, Adelson ME, Mordechai E and Trama JP. CIP2A protein expression in high-grade, high-stage bladder cancer. Cancer medicine. 2012; 1(1):76-81.
61. Xue Y, Wu G, Wang X, Zou X, Zhang G, Xiao R, Yuan Y, Long D, Yang J, Wu Y, Xu H, Liu F and Liu M. CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma. Medical oncology. 2013; 30(1):406.
62. Fang Y, Li Z, Wang X and Zhang S. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2012; 33(6):2299-2306.
63. Bockelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, Butzow R and Ristimaki A. Prognostic role of CIP2A expression in serous ovarian cancer. British journal of cancer. 2011; 105(7):989-995.
64. Xu P, Huang Q, Xie F, Xu XL and Shao F. Increased expression of CIP2A in cholangiocarcinoma and correlation with poor prognosis. Hepato-gastroenterology. 2013; 60(124):669-672.
65. Ren J, Li W, Yan L, Jiao W, Tian S, Li D, Tang Y, Gu G, Liu H and Xu Z. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival. British journal of cancer. 2011; 105(12):1905-1911.
66. Bockelman C, Hagstrom J, Makinen LK, Keski-Santti H, Hayry V, Lundin J, Atula T, Ristimaki A and Haglund C. High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. British journal of cancer. 2011; 104(12):1890-1895.
67. Huang LP, Adelson ME, Mordechai E and Trama JP. CIP2A expression is elevated in cervical cancer. Cancer biomarkers: section A of Disease markers. 2010; 8(6):309-317.
68. Liu J, Wang X, Zhou G, Wang H, Xiang L, Cheng Y, Liu W, Wang Y, Jia J and Zhao W. Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein. Gynecologic oncology. 2011; 122(2):430-436.
69. Vaarala MH, Vaisanen MR and Ristimaki A. CIP2A expression is increased in prostate cancer. Journal of experimental & clinical cancer research: CR. 2010; 29:136.
70. Katz J, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I, Cha S and Chan EK. CIP2A expression and localization in oral carcinoma and dysplasia. Cancer biology & therapy. 2010; 10(7):694-699.
71. Basile JR and Czerninski R. The role of CIP2A in oral squamous cell carcinoma. Cancer biology & therapy. 2010; 10(7):700-702.
72. Jung HM, Patel RS, Phillips BL, Wang H, Cohen DM, Reinhold WC, Chang LJ, Yang LJ and Chan EK. Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. Molecular biology of the cell. 2013; 24(11):1638-1648, S1631-1637.
73. Li Y, Wang K, Dai L, Wang P, Song C, Shi J, Ren P, Ye H and Zhang J. HapMap-based study of CIP2A gene polymorphisms and HCC susceptibility. Oncology letters. 2012; 4(2):358-364.
74. He H, Wu G, Li W, Cao Y and Liu Y. CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis. Diagnostic molecular pathology: the American journal of surgical pathology, part B. 2012; 21(3):143-149.
75. Huang P, Qiu J, You J, Hong J, Li B, Zhou K, Chen G, Yuan Y and Zou R. Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals. 2012; 17(5):422-429.
76. Wei Y, Du Y, Chen X, Li P, Wang Y, Zang W, Zhao L, Li Z and Zhao G. Expression patterns of microRNA-218 and its potential functions by targeting CIP2A and BMI1 genes in melanoma. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014.
77. Wang J, Li W, Li L, Yu X, Jia J and Chen C. CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. International journal of laboratory hematology. 2011; 33(3):290-298.
78. Li N, Abe S, Kurata M, Abe-Suzuki S, Onishi I, Kirimura S, Murayama T, Hidaka M, Kawano F and Kitagawa M. Over-Expression of Cancerous Inhibitor of PP2A (CIP2A) in Bone Marrow Cells from Patients with a Group of High-Risk Myelodysplastic Syndromes. Pathology oncology research: POR. 2013.
79. Lilja L, Haapasaari KM, Bloigu R, Salonen T, Ristimaki A, Turpeenniemi-Hujanen T and Kuittinen O. Increased expression of CIP2A in aggressive subtypes of B-cell lymphoma. Histopathology. 2013; 63(3):438-439.
80. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR and Clark RE. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood. 2011; 117(24):6660-6668.
81. Coenen EA, Zwaan CM, Meyer C, Marschalek R, Pieters R, van der Veken LT, Beverloo HB and van den Heuvel-Eibrink MM. KIAA1524: A novel MLL translocation partner in acute myeloid leukemia. Leukemia research. 2011; 35(1):133-135.
82. Pippa R, Dominguez A, Christensen DJ, Moreno-Miralles I, Blanco-Prieto MJ, Vitek MP and Odero MD. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia. SET binding drugs have antagonistic activity. Leukemia. 2014.
83. Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ and Odero MD. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia. 2011; 25(4):606-614.
84. Cristobal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, Garcia-Sanchez MA, Calasanz MJ and Odero MD. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica. 2012; 97(4):543-550.
85. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012; 2(5):401-404.
86. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1.
87. Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T and Westermarck J. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PloS one. 2011; 6(3):e17979.
88. Pallai R, Bhaskar A, Sodi V and Rice LM. Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells. Transcription. 2012; 3(6):323-335.
89. Liu X, Chai Y, Li J, Ren P, Liu M, Dai L, Qian W, Li W and Zhang JY. Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014.
90. Hou DR, Huang AC, Shiau CW, Wang CY, Yu HC and Chen KF. Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition. Molecules. 2013; 18(12):15398-15411.
91. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ and Cheng AL. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene. 2010; 29(47):6257-6266.
92. Liu CY, Shiau CW, Kuo HY, Huang HP, Chen MH, Tzeng CH and Chen KF. Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells. Haematologica. 2013; 98(5):729-738.
93. Huang LP, Libby, E, Trama, J. (2011). Identify and evaluate novel biomarker CIP2A for cervical cancer diagnostics. AACR 102nd Annual Meeting. (Orlando Florida: Cancer Research).
94. Huang L. AM, Mordechai E., Trama J. (2011). Cancerous Inihibitor of PP2A (CIP2A) expression for bladder cancer diagnosis. AACR Cancer Research).
95. Peng B. LS, Quian W., Chan E., Tan E., Zhang J. (2010). Immune response to fetal oncoprotein p90/CIP2A in lung cancer. AACR: Cancer Research).
96. Xu P, Xu XL, Huang Q, Zhang ZH and Zhang YB. CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis. Medical oncology. 2012; 29(3):1643-1647.
97. Shi F, Ding Y, Ju S, Wu X and Cao S. Expression and prognostic significance of CIP2A in cutaneous malignant melanoma. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals. 2014; 19(1):70-76.
98. Teng HW, Yang SH, Lin JK, Chen WS, Lin TC, Jiang JK, Yen CC, Li AF, Chen PC, Lan YT, Lin CC, Hsu YN, Wang HW and Chen KF. CIP2A is a predictor of poor prognosis in colon cancer. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract. 2012; 16(5):1037-1047.
99. Peng XY, Chen W, Zhou K, Fu JP, Fu P and Zeng QL. [Expression of cancerous inhibitor of protein phosphatase 2A in tissue microarray of colorectal cancer and its clinical significance]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery. 2013; 16(11):1102-1106.
100. Liu Z, Ma L, Wen ZS, Hu Z, Wu FQ, Li W, Liu J and Zhou GB. Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Carcinogenesis. 2013.
101. Cantini L, Attaway CC, Butler B, Andino LM, Sokolosky ML and Jakymiw A. Fusogenic-oligoarginine peptide-mediated delivery of siRNAs targeting the CIP2A oncogene into oral cancer cells. PloS one. 2013; 8(9):e73348.
102. Liu Z, Ma L, Wen ZS, Cheng Y-X and Zhou GB. Ethoxysanguinarine Induces Inhibitory Effects and Downregulates CIP2A in Lung Cancer Cells. ACS Med Chem Lett. 2014; 5(2):113-118.
103. Shiau C-W. (2012). Development of Erlotinib derivatives as CIP2A inhibitors. AACR 103rd Annual meeting. (Chicago IL: Cancer Research).
104. Ting-Ting Chao, Cheng Yi Wang, Fang-Yu Chang, Yen-Lin Chen, Chung-Wai Shiau and Chen K-F. (2013). CIP2A is a novel therapeutic target for an erlotinib derivative in EGFR wild-type NSCLC cells. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. (Boston, MA. Philadelphia (PA), pp. Abstract nr C185.
105. Yu HC, Chen HJ, Chang YL, Liu CY, Shiau CW, Cheng AL and Chen KF. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochemical pharmacology. 2013; 85(3):356-366.
106. Chen KF, Pao KC, Su JC, Chou YC, Liu CY, Chen HJ, Huang JW, Kim I and Shiau CW. Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorganic & medicinal chemistry. 2012; 20(20):6144-6153.
107. Yu HC, Hou DR, Liu CY, Lin CS, Shiau CW, Cheng AL and Chen KF. Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome. PloS one. 2013; 8(2):e55705.
108. Lin YC, Chen KC, Chen CC, Cheng AL and Chen KF. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral oncology. 2012; 48(7):585-593.
109. Chen KF, Yu HC, Liu CY, Chen HJ, Chen YC, Hou DR, Chen PJ and Cheng AL. Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A. Molecular cancer therapeutics. 2011; 10(5):892-901.
110. Huang CY, Wei CC, Chen KC, Chen HJ, Cheng AL and Chen KF. Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A. Cancer letters. 2012; 317(1):9-15.
111. Tseng L. LC, Chang K., Shiau C., Cheng A., Kuo H., Tzeng C., Chen K. CIP2A mediates the apoptotic effect of bortezomib on triple negative breast cancer. Cancer research. 2011; 71.
112. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW and Chen KF. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast cancer research: BCR. 2012; 14(2):R68.
113. Ling-Min Tseng, Chun-Yu Liu, Kung-Chi Chang, Duen-Shian Wang, Chung-Wai Shiau and Chen. K-F. (2013). CIP2A mediates the effect of tamoxifen-induced apoptosis in estrogen receptor negative breast cancer cells. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research (Washington, DC.: AACR).
114. Wang HW, Yang SH, Huang GD, Lin JK, Chen WS, Jiang JK, Lan YT, Lin CC, Hwang WL, Tzeng CH, Li AF, Yen CC and Teng HW. Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism. Journal of cancer research and clinical oncology. 2014.
115. De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR and Dey N. Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness. Neoplasia. 2014; 16(1):43-72.
116. Avtanski DB, Nagalingam A, Bonner MY, Arbiser JL, Saxena NK and Sharma D. Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis. Mol Oncol. 2014.
117. Baumgart A, Mazur PK, Anton M, Rudelius M, Schwamborn K, Feuchtinger A, Behnke K, Walch A, Braren R, Peschel C, Duyster J, Siveke JT and Dechow T. Opposing role of Notch1 and Notch2 in a Kras-driven murine non-small cell lung cancer model. Oncogene. 2014.
118. Hiraga R, Kato M, Miyagawa S and Kamata T. Nox4-derived ROS signaling contributes to TGF-beta-induced epithelial-mesenchymal transition in pancreatic cancer cells. Anticancer Res. 2013; 33(10):4431-4438.
119. Li L, Wang J, Zhang Y, Zhang Y, Ma L, Weng W, Qiao Y, Xiao W, Wang H, Yu W, Pan Q, He Y and Sun F. MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer. FEBS letters. 2013; 587(24):3921-3927.
120. Gough NR. Focus issue: From genomic mutations to oncogenic pathways. Science signaling. 2013; 6(268):eg3.
121. Ventela S, Come C, Makela JA, Hobbs RM, Mannermaa L, Kallajoki M, Chan EK, PandolfiPP, Toppari J and Westermarck J. CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice. PloS one. 2012; 7(3):e33209.
122. Wang J, Li W, Li L, Yu X, Jia J and Chen C. CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. International journal of laboratory hematology. 2011; 33(3):290-298.
123. Yi F, Ni W, Liu W, Bai J and Li W. Expression and biological role of CIP2A in human astrocytoma. Molecular medicine reports. 2013; 7(5):1376-1380.
124. Huang LP, Savoly D, Sidi AA, Adelson ME, Mordechai E and Trama JP. CIP2A protein expression in high-grade, high-stage bladder cancer. Cancer medicine. 2012; 1(1):76-81.
125. Xue Y, Wu G, Wang X, Zou X, Zhang G, Xiao R, Yuan Y, Long D, Yang J, Wu Y, Xu H, Liu F and Liu M. CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma. Medical oncology. 2013; 30(1):406.
126. Yu G, Liu G, Dong J and Jin Y. Clinical implications of CIP2A protein expression in breast cancer. Medical oncology. 2013; 30(2):524.
127. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thezenas S and Westermarck J. CIP2A is associated with human breast cancer aggressivity. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(16):5092-5100.
128. Liu X, Chai Y, Li J, Ren P, Liu M, Dai L, Qian W, Li W and Zhang JY. Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35(3):2661-2667.
129. Choi YA, Park JS, Park MY, Oh KS, Lee MS, Lim JS, Kim KI, Kim KY, Kwon J, Yoon do Y, Moon EY and Yang Y. Increase in CIP2A expression is associated with doxorubicin resistance. FEBS letters. 2011; 585(5):755-760.
130. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW and Chen KF. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast cancer research: BCR. 2012; 14(2):R68.
131. Huang LP, Adelson ME, Mordechai E and Trama JP. CIP2A expression is elevated in cervical cancer. Cancer biomarkers: section A of Disease markers. 2010; 8(6):309-317.
132. Xu P, Huang Q, Xie F, Xu XL and Shao F. Increased expression of CIP2A in cholangiocarcinoma and correlation with poor prognosis. Hepato-gastroenterology. 2013; 60(124):669-672.
133. Teng HW, Yang SH, Lin JK, Chen WS, Lin TC, Jiang JK, Yen CC, Li AF, Chen PC, Lan YT, Lin CC, Hsu YN, Wang HW and Chen KF. CIP2A is a predictor of poor prognosis in colon cancer. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract. 2012; 16(5):1037-1047.
134. Cristobal I, Manso R, Rincon R, Carames C, Senin C, Borrero A, Martinez-Useros J, Rodriguez M, Zazo S, Aguilera O, Madoz-Gurpide J, Rojo F and Garcia-Foncillas J. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Molecular cancer therapeutics. 2014; 13(4):938-947.
135. Bockelman C, Koskensalo S, Hagstrom J, Lundin M, Ristimaki A and Haglund C. CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer biology & therapy. 2012; 13(5):289-295.
136. Shi F, Ding Y, Ju S, Wu X and Cao S. Expression and prognostic significance of CIP2A in cutaneous malignant melanoma. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals. 2014; 19(1):70-76.
137. Rantanen T, Kauttu T, Akerla J, Honkanen T, Krogerus L, Salo J, Paavonen T and Oksala N. CIP2A expression and prognostic role in patients with esophageal adenocarcinoma. Medical oncology. 2013; 30(3):684.
138. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J and Ristimaki A. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. Journal of the National Cancer Institute. 2009; 101(11):793-805.
139. Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J and Xu D. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(12):3722-3728.
140. Zhao Y, Li Y, Han J, Liu T, Guan Q, Zhao P, Guo L, Liu K and He D. Helicobacter pylori enhances CIP2A expression and cell proliferation via JNK2/ATF2 signaling in human gastric cancer cells. International journal of molecular medicine. 2014; 33(3):703-710.
141. Lin YC, Chen KC, Chen CC, Cheng AL and Chen KF. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral oncology. 2012; 48(7):585-593.
142. He H, Wu G, Li W, Cao Y and Liu Y. CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis. Diagnostic molecular pathology: the American journal of surgical pathology, part B. 2012; 21(3):143-149.
143. Li N, Abe S, Kurata M, Abe-Suzuki S, Onishi I, Kirimura S, Murayama T, Hidaka M, Kawano F and Kitagawa M. Over-Expression of Cancerous Inhibitor of PP2A (CIP2A) in Bone Marrow Cells from Patients with a Group of High-Risk Myelodysplastic Syndromes. Pathology oncology research: POR. 2013.
144. Ma L, Wen ZS, Liu Z, Hu Z, Ma J, Chen XQ, Liu YQ, Pu JX, Xiao WL, Sun HD and Zhou GB. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PloS one. 2011; 6(5):e20159.
145. Schmidt MK, Meurer L, Volkweis BS, Edelweiss MI, Schirmer CC, Kruel CD and Gurski RR. c-Myc overexpression is strongly associated with metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus/ISDE. 2007; 20(3):212-216.
146. Jung HM, Patel RS, Phillips BL, Wang H, Cohen DM, Reinhold WC, Chang LJ, Yang LJ and Chan EK. Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. Molecular biology of the cell. 2013; 24(11):1638-1648, S1631-1637.
147. Khanna A, Kauko O, Bockelman C, Laine A, Schreck I, Partanen JI, Szwajda A, Bormann S, Bilgen T, Helenius M, Pokharel YR, Pimanda J, Russel MR, Haglund C, Cole KA, Klefstrom J, et al. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. Cancer research. 2013; 73(22):6757-6769.
148. Xu P, Xu XL, Huang Q, Zhang ZH and Zhang YB. CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis. Medical oncology. 2012; 29(3):1643-1647.
149. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ and Wang EH. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Annals of surgical oncology. 2011; 18(3):857-865.
150. Liu Z, Ma L, Wen ZS, Hu Z, Wu FQ, Li W, Liu J and Zhou GB. Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Carcinogenesis. 2014; 35(4):905-914.
151. Katz J, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I, Cha S and Chan EK. CIP2A expression and localization in oral carcinoma and dysplasia. Cancer biology & therapy. 2010; 10(7):694-699.
152. Basile JR and Czerninski R. The role of CIP2A in oral squamous cell carcinoma. Cancer biology & therapy. 2010; 10(7):700-702.
153. Zhai M, Cong L, Han Y and Tu G. CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35(2):1123-1128.
154. Fang Y, Li Z, Wang X and Zhang S. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2012; 33(6):2299-2306.
155. Wang L, Gu F, Ma N, Zhang L, Bian JM and Cao HY. CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34(4):2309-2313.
156. Vaarala MH, Vaisanen MR and Ristimaki A. CIP2A expression is increased in prostate cancer. Journal of experimental & clinical cancer research: CR. 2010; 29:136.
157. Ren J, Li W, Yan L, Jiao W, Tian S, Li D, Tang Y, Gu G, Liu H and Xu Z. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival. British journal of cancer. 2011; 105(12):1905-1911.
158. Bockelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, Butzow R and Ristimaki A. Prognostic role of CIP2A expression in serous ovarian cancer. British journal of cancer. 2011; 105(7):989-995.
159. Bockelman C, Hagstrom J, Makinen LK, Keski-Santti H, Hayry V, Lundin J, Atula T, Ristimaki A and Haglund C. High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. British journal of cancer. 2011; 104(12):1890-1895.